摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-tert-butyl 3-((5,6,7,8-tetrahydroquinolin-8-ylamino)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate | 1380336-41-3

中文名称
——
中文别名
——
英文名称
(S)-tert-butyl 3-((5,6,7,8-tetrahydroquinolin-8-ylamino)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate
英文别名
tert-butyl 3-[[[(8S)-5,6,7,8-tetrahydroquinolin-8-yl]amino]methyl]-3,4-dihydro-1H-isoquinoline-2-carboxylate
(S)-tert-butyl 3-((5,6,7,8-tetrahydroquinolin-8-ylamino)methyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate化学式
CAS
1380336-41-3
化学式
C24H31N3O2
mdl
——
分子量
393.529
InChiKey
DSKMXZNMDURGBN-LBAQZLPGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    29
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    54.5
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR CXCR4 DE CHIMIOKINE ET LEURS UTILISATIONS
    申请人:UNIV EMORY
    公开号:WO2018156595A1
    公开(公告)日:2018-08-30
    The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.
    该披露涉及趋化因子CXCR4受体调节剂及其相关用途。这些受体调节剂可以配制成包含所披露的化合物或其药学上可接受的盐或前药的药物组合物。这些组合物可用于管理与CXCR4相关的疾病,通常用于预防或治疗病毒感染、异常细胞增殖、视网膜退化、炎症性疾病,或作为免疫刺激剂或免疫抑制剂,或用于癌症管理,并可与另一种活性成分一起给药,如抗病毒药物或化疗药物。
  • FUSED AZINES AS CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO
    申请人:Emory University
    公开号:EP3153510A1
    公开(公告)日:2017-04-12
    The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
    本公开涉及趋化因子 CXCR4 受体调节剂及其相关用途。在某些实施方案中,本公开涉及包含本文公开的化合物或其药学上可接受的盐或原药的药物组合物。在某些实施方案中,本文公开的组合物用于控制与CXCR4相关的病症,通常是预防或治疗病毒感染如HIV或控制癌症。
  • Chemokine CXCR4 receptor modulators and uses related thereto
    申请人:EMORY UNIVERSITY
    公开号:US10016408B2
    公开(公告)日:2018-07-10
    The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
    本公开涉及趋化因子 CXCR4 受体调节剂及其相关用途。在某些实施方案中,本公开涉及包含本文公开的化合物或其药学上可接受的盐或原药的药物组合物。在某些实施方案中,本文公开的组合物用于控制与CXCR4相关的病症,通常是预防或治疗病毒感染如HIV或控制癌症。
  • CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USES RELATED THERETO
    申请人:Emory University
    公开号:EP2646430B1
    公开(公告)日:2016-09-21
  • CHEMOKINE CXCR4 RECEPTOR MODULATORS AND USED RELATED THERETO
    申请人:EMORY UNIVERSITY
    公开号:US20150157630A1
    公开(公告)日:2015-06-11
    The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising compounds disclosed herein or pharmaceutically acceptable salts or prodrugs thereof. In certain embodiments, the compositions disclosed herein are used for managing CXCR4 related conditions, typically prevention or treatment of viral infections such as HIV or for managing cancer.
查看更多